Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846743 | 0.90 | HDAC1 (0.47) | HDAC1HDAC2SUCNR1LTB4RP2RY12 | |
| SCHEMBL847238 | 0.86 | SUCNR1 (0.60) | SUCNR1CNR2 | |
| SCHEMBL846739 | 0.84 | LTB4R (0.43) | HDAC1HDAC2LTB4RCNR2CES1 | |
| SCHEMBL7845227 | 0.83 | MTNR1A (0.44) | HDAC1HDAC2LTB4RCNR2CES1 | |
| Hydrochloric Acid SCHEMBL847470 | 0.82 | MTNR1A (0.43) | HDAC1HDAC2LTB4RCNR2CES1 | |
| SCHEMBL861993 | 0.81 | LTB4R (0.41) | HDAC1HDAC2LTB4RCNR2CES1 | |
| SCHEMBL846487 | 0.79 | CTSA (0.40) | HDAC1HDAC2SUCNR1LTB4RCNR2 | |
| SCHEMBL846498 | 0.78 | MEN1 (0.49) | HDAC1HDAC2CNR2CES1FAAH | |
| SCHEMBL7170143 | 0.78 | CNR2 (0.44) | CNR2CES1FAAHNCEH1P2RY12 | |
| SCHEMBL31286721 | 0.75 | MAPK1 (0.43) | HDAC1HDAC2P2RY12HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | HDAC1 1450/4885HDAC2 2204/4885SUCNR1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.